Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS) by Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials by Bafadhel, M, Peterson, S, Blas, D, Calverley, P, Rennard, S, Richter, K, Fagerås, M

Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD by Bafadhel, M, Singh, D, Jenkins, C, Peterson, S, Bengtsson, T, Wessman, P, Fageras, M

Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis by Bafadhel, M, Peterson, S, De Blas, M, Calverley, P, Rennard, S, Richter, K, Fageras, M

The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials by Eriksson G, Calverley PM, Jenkins CR, Anzueto AR, Make BJ, Lindberg M, Fagerås M, Postma DS

Get full text

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD by Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, Fagerås M, Postma DS

Get full text